EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Kissei Pharmaceutical Co. Ltd (KSPHF) fair value: what the stock is really worth

As of Sep 18, 2026: fair value of Kissei Pharmaceutical Co. Ltd $35.83, price $25.77, upside +39.0%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

KP Kissei Pharmaceutical Co. Ltd logo Broad data Sep 24, 2026

Kissei Pharmaceutical Co. Ltd

KSPHF · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $35.83 · Undervalued (+39%)
!Quality 47/100
!Expensive Growth (revenue 5y +7.3 %/yr)
✓Solidly profitable · 14.2% net margin (TTM)
!Low debt · negative free cash flow
·3.22% dividend yield
✓Ranks above peers (8/13)
!Narrow moat 34/100
!Weak on past: 25 out of 100
Watch Kissei Pharmaceutical Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$30.62 $14.26 Fair Value $35.83 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $14.26 – $30.62 · fair‑value band $26.87 – $44.78 · the $25.77 price screens below the $35.83 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Kissei Pharmaceutical Co. in your weekly email

Every Wednesday you see whether Kissei Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan.

Show more

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. Kissei Pharmaceutical Co., Ltd. was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.

Stock analysis

Kissei Pharmaceutical Co. Ltd (KSPHF) currently trades at $25.77, while our model-based Fair Value estimate is $35.83, implying the stock looks roughly 28.1% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $97.92 per share, and 9 of the 11 models we run sit above the $25.77 price.

Bear case: the Asset-Based group reads lowest at $23.59, and 2 of the 11 models stay below the price. Evidence for this calculation is high.

Scenario range: $26.87 (bear) to $44.78 (bull), the price of $25.77 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Kissei Pharmaceutical Co. Ltd reported revenue of ¥98.0B in FY2026 versus ¥65.4B in FY2022, a compound +10.7%/yr. Reported net income was ¥13.9B in FY2026, compounding +1.8%/yr from FY2022.

Key figures

Market cap $1.1B · P/E ratio 12.4 · P/S ratio 1.76 · EPS (TTM) $2.07 · Dividend yield 3.2% · Net margin 14.1% · Return on equity 6.3% · Return on assets (EBIT) −27.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 39%, KSPHF screens cheaper than that median.

Fair Value models

Bear $26.87 Fair Value $35.83 Bull $44.78
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings $30.88 $59.23 $111.84 70
Residual Income $26.07 $26.24 $24.64 68
EV/EBITDA $7.20 $8.12 $9.04 67
All 11 models by family
DCF Models
Owner Earnings $30.88 $59.23 $111.84 70
Earnings-Based
Graham-Dodd $14.33 $99.95 $140.26 61
Lynch FV $51.64 $73.77 $95.90 59
PEG = 1.0 $51.64 $73.77 $95.90 55
Multiples
P/E Multiple $34.78 $46.37 $57.96 63
P/S Multiple $26.87 $35.83 $44.79 58
P/B Multiple $26.87 $35.83 $44.79 55
EV/EBITDA $7.20 $8.12 $9.04 67
Asset-Based
NCAV (Graham) $17.60 $23.59 $35.20 54
Economic Profit
Residual Income $26.07 $26.24 $24.64 68
Growth Earnings
Growth-Adj P/E $68.54 $97.92 $127.30 65

Open the full fair value analysis →

Notify me when KSPHF reaches fair value

Put KSPHF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 46 · Market factors (momentum, volatility) 46

Profitability 37
Margins and returns on capital today
Quality Growth 34
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 63
Balance sheet, leverage, solvency risk
Investment 51
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 37
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 47/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2021 (pandemic). Over 10 years: +65.5% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+27.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.1%
Dividend (yield on the price)3.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.24% vs 72%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → −3%
Start year 2021 (pandemic)

Watch KSPHF, get fair value alerts →

Compare Kissei Pharmaceutical Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +39% · Top 25%
Profitability
Return on equity (TTM) 6% · Below median
Return on assets −1% · Bottom 25%
Net margin (TTM) 14% · Top 25%
Operating margin (TTM) 3% · Below median
Growth and dividend
Revenue growth 9% · Above median
Dividend yield (TTM) 3.2% · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 12.4× · Cheapest 25%
P/B 0.73× · Cheapest 25%
P/S (TTM) 1.75× · Cheaper than median
EV/EBITDA 82.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)85 · sector 14
FUTURE (revenue growth)47 · sector 21
PAST (return on equity)25 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)64 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kissei Pharmaceutical Co. Ltd · Fair Value
$35.83 +28%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Kissei Pharmaceutical Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/KSPHF

Frequently asked questions

Is Kissei Pharmaceutical Co. Ltd (KSPHF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $35.83 versus a price of $25.77, about +39% upside (undervalued).
What is the fair value of KSPHF?
Our model-based fair value for Kissei Pharmaceutical Co. Ltd is $35.83 (as of Sep 24, 2026), built from audited fundamentals. The current price: $25.77.
What is the quality score of KSPHF?
Kissei Pharmaceutical Co. Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kissei Pharmaceutical Co. Ltd (KSPHF)?
Our model-based price target is the fair value of $35.83 (as of Sep 24, 2026) from 11 valuation models. Cautious scenario $26.87, optimistic scenario $44.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Kissei Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at $35.83, about +39% upside versus a price of $25.77 (undervalued). Cautious scenario $26.87, optimistic scenario $44.78. The calculation is refreshed regularly with new filings.
What is the revenue of Kissei Pharmaceutical Co. Ltd (KSPHF)?
Kissei Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about ¥97.4B (latest available figure, as of Sep 24, 2026).
Does Kissei Pharmaceutical Co. Ltd pay a dividend?
Kissei Pharmaceutical Co. Ltd currently shows a dividend yield of about 3.22% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Kissei Pharmaceutical Co. Ltd (KSPHF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kissei Pharmaceutical Co. Ltd it is $35.83 per share (as of Sep 24, 2026), against a price of $25.77. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Kissei Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, KSPHF trades below its calculated fair value: price $25.77, fair value $35.83, a gap of about +39% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KSPHF?
No. The price is what the market pays today ($25.77); the fair value is what the company's own numbers justify ($35.83). For Kissei Pharmaceutical Co. Ltd the two are $10.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kissei Pharmaceutical Co. Ltd worth?
The market values Kissei Pharmaceutical Co. Ltd at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $25.77; our models calculate a fair value of $35.83 per share.
What do the bullish and bearish scenarios say about KSPHF?
Our models span a range for Kissei Pharmaceutical Co. Ltd: cautious scenario $26.87, base $35.83, optimistic $44.78 per share (as of Sep 24, 2026, price $25.77). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KSPHF?
Kissei Pharmaceutical Co. Ltd trades at a price-to-earnings ratio of 12.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $35.83 is built from several models across several years. Other multiples: P/B 0.7, P/S 1.7, EV/EBITDA 82.0.
How solid is the balance sheet of Kissei Pharmaceutical Co. Ltd (KSPHF)?
Balance-sheet figures for Kissei Pharmaceutical Co. Ltd (as of Sep 24, 2026): return on equity 6.3%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is KSPHF from its 52-week high?
Kissei Pharmaceutical Co. Ltd trades at $25.77, about 16% below its 52-week high of $30.62 and 7% above the low of $24.09 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $35.83 is for.
Which stocks are comparable to Kissei Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kissei Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $25.77, calculated fair value $35.83 (+39%), Quality Score 47/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KSPHF calculated?
We run Kissei Pharmaceutical Co. Ltd through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $35.83, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Kissei Pharmaceutical Co. Ltd currently trades 39 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The closing price on Sep 18, 2026 was $25.77. Our model-based fair value is $35.83, about +39% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kissei Pharmaceutical Co. Ltd right now?
The price is below even our cautious bear case ($26.87). The market is more pessimistic than our downside scenario. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Kissei Pharmaceutical Co. Ltd (KSPHF) come from?
Earnings per share at Kissei Pharmaceutical Co. Ltd grew +21.6 % a year from 2015 to 2026. Broken into its drivers: revenue per share +17.1 %, EBIT margin −7.8 %, tax rate +1.4 %, residual (interest, one-offs) +11.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Kissei Pharmaceutical Co. Ltd

How large is the market capitalisation of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The market capitalisation of Kissei Pharmaceutical Co. Ltd is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The price-to-sales ratio of Kissei Pharmaceutical Co. Ltd is 1.76 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kissei Pharmaceutical Co. Ltd (KSPHF)?
Earnings per share at Kissei Pharmaceutical Co. Ltd are $2.07 (price ÷ EPS = P/E 12.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The dividend yield of Kissei Pharmaceutical Co. Ltd is 3.2% (payout 40.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The net margin of Kissei Pharmaceutical Co. Ltd is 14.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The return on equity (ROE) of Kissei Pharmaceutical Co. Ltd is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kissei Pharmaceutical Co. Ltd (KSPHF)?
On an EBIT basis the return on assets of Kissei Pharmaceutical Co. Ltd is −27.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kissei Pharmaceutical Co. Ltd (KSPHF)?
The operating margin of Kissei Pharmaceutical Co. Ltd is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kissei Pharmaceutical Co. Ltd (KSPHF)?
Revenue at Kissei Pharmaceutical Co. Ltd is growing +9.3% versus a year earlier (3y avg +13.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kissei Pharmaceutical Co. Ltd (KSPHF)?
Earnings per share at Kissei Pharmaceutical Co. Ltd are growing −8.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kissei Pharmaceutical Co. Ltd (KSPHF) generate?
The free cash flow of Kissei Pharmaceutical Co. Ltd is −¥6.4B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kissei Pharmaceutical Co. Ltd (KSPHF) hold?
Kissei Pharmaceutical Co. Ltd holds more cash than debt, ¥28.0B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kissei Pharmaceutical Co. Ltd in the live analysis

One click puts Kissei Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.